BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
Titan Company Ltd.’s Q3 FY23 business update point out that company has witnessed standalone revenue growth of 12.0%, while Titan Engineering and Automation Ltd. grew 58.0%; Caratlane grew at 50.0% YoY, driven by-
new buyer growth in the festive season,
strong marketing campaign and
network expansion.
Jewelry sales witnessed growth of 11.0% wherein Tanishq opened its first international store in the USA. Studded jewelry reported higher growth than overall divisions led by activations driven by higher contribution from premiumsiation. In Q3, Titan added 111 stores across divisions/ formats.
Watches and wearables achieved 14.0% growth led by strong traction in the wearables space. Sales from Titan Eye+ stores and distribution channel showcased similar growth with overall division.
We believe the continued sales momentum across business divisions would have positive impact on the organized Jewelry.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Real Estate Vs Gold: Which Is Better Investment Option In 2025


High Gold Rates Could See Shifts In Demand Segments, Titan Says


Markets May See Rally In Near-Term But Earnings Growth Crucial For Momentum: Ambit Investment Managers MD


Divi’s Laboratories Q4 Results Review: Systematix Retains 'Sell' On Rich Valuations
